National Pension Service Buys 11,524 Shares of Edwards Lifesciences Corporation $EW

National Pension Service grew its stake in Edwards Lifesciences Corporation (NYSE:EW) by 1.2% in the fourth quarter, HoldingsChannel reports. The fund owned 935,283 shares of the medical research company’s stock after acquiring an additional 11,524 shares during the period. National Pension Service’s holdings in Edwards Lifesciences were worth $79,733,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Edwards Lifesciences by 13.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock worth $6,706,000 after buying an additional 10,078 shares during the last quarter. Atlantic Union Bankshares Corp raised its stake in shares of Edwards Lifesciences by 2,240.9% during the third quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock worth $925,000 after buying an additional 11,384 shares during the last quarter. Washington Trust Advisors Inc. raised its stake in shares of Edwards Lifesciences by 15.6% during the third quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company’s stock worth $10,156,000 after buying an additional 17,625 shares during the last quarter. Azzad Asset Management Inc. ADV raised its stake in shares of Edwards Lifesciences by 330.5% during the third quarter. Azzad Asset Management Inc. ADV now owns 21,227 shares of the medical research company’s stock worth $1,651,000 after buying an additional 16,296 shares during the last quarter. Finally, Elo Mutual Pension Insurance Co raised its stake in shares of Edwards Lifesciences by 39.9% during the third quarter. Elo Mutual Pension Insurance Co now owns 89,674 shares of the medical research company’s stock worth $6,974,000 after buying an additional 25,562 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Stock Up 0.5%

Shares of NYSE:EW opened at $86.41 on Friday. The company has a market capitalization of $49.76 billion, a PE ratio of 45.96, a PEG ratio of 2.17 and a beta of 0.87. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $88.28. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. The company has a 50 day moving average price of $81.73 and a two-hundred day moving average price of $83.01.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the transaction, the chief financial officer owned 39,699 shares of the company’s stock, valued at $3,177,507.96. This trade represents a 24.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 106,397 shares of company stock worth $8,848,664 over the last quarter. 0.31% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. UBS Group reaffirmed a “neutral” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Robert W. Baird upped their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Evercore reaffirmed an “outperform” rating and issued a $93.00 target price on shares of Edwards Lifesciences in a research note on Friday, April 24th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $95.65.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.